345 related articles for article (PubMed ID: 16151405)
21. Antibody cocktails: next-generation biopharmaceuticals with improved potency.
Logtenberg T
Trends Biotechnol; 2007 Sep; 25(9):390-4. PubMed ID: 17681390
[TBL] [Abstract][Full Text] [Related]
22. Antibody engineering and modification technologies.
Filpula D
Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
[TBL] [Abstract][Full Text] [Related]
23. Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody responses in transgenic mice.
Suárez E; Magadán S; Sanjuán I; Valladares M; Molina A; Gambón F; Díaz-Espada F; González-Fernández A
Mol Immunol; 2006 Apr; 43(11):1827-35. PubMed ID: 16343622
[TBL] [Abstract][Full Text] [Related]
24. Human antibodies by design.
Vaughan TJ; Osbourn JK; Tempest PR
Nat Biotechnol; 1998 Jun; 16(6):535-9. PubMed ID: 9624683
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
26. Antibody engineering for the development of therapeutic antibodies.
Kim SJ; Park Y; Hong HJ
Mol Cells; 2005 Aug; 20(1):17-29. PubMed ID: 16258237
[TBL] [Abstract][Full Text] [Related]
27. Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous V(H) genes.
de Kruif J; Kramer A; Visser T; Clements C; Nijhuis R; Cox F; van der Zande V; Smit R; Pinto D; Throsby M; Logtenberg T
J Mol Biol; 2009 Apr; 387(3):548-58. PubMed ID: 19361421
[TBL] [Abstract][Full Text] [Related]
28. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal and recombinant antibodies, 30 years after ..
Laffly E; Sodoyer R
Hum Antibodies; 2005; 14(1-2):33-55. PubMed ID: 16424599
[TBL] [Abstract][Full Text] [Related]
30. Historical development of monoclonal antibody therapeutics.
Nissim A; Chernajovsky Y
Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
[TBL] [Abstract][Full Text] [Related]
31. Molecular dissection of antibody responses against pneumococcal surface protein A: evidence for diverse DH-less heavy chain gene usage and avidity maturation.
Rohatgi S; Dutta D; Tahir S; Sehgal D
J Immunol; 2009 May; 182(9):5570-85. PubMed ID: 19380805
[TBL] [Abstract][Full Text] [Related]
32. Transgenic plants as factories for biopharmaceuticals.
Giddings G; Allison G; Brooks D; Carter A
Nat Biotechnol; 2000 Nov; 18(11):1151-5. PubMed ID: 11062432
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials of gene/biotechnology products.
Röthig HJ
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):539-44. PubMed ID: 7885081
[TBL] [Abstract][Full Text] [Related]
34. Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity.
Qian W; Wang L; Li B; Wang H; Hou S; Hong X; Zhang D; Guo Y
Biochem Biophys Res Commun; 2008 Mar; 367(2):497-502. PubMed ID: 18190781
[TBL] [Abstract][Full Text] [Related]
35. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
Muller PY; Brennan FR
Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
[TBL] [Abstract][Full Text] [Related]
36. Production of an anti-mouse MHC class II monoclonal antibody with biological activity in transgenic tobacco.
Hong SY; Kim TG; Kwon TH; Jang YS; Yang MS
Protein Expr Purif; 2007 Jul; 54(1):134-8. PubMed ID: 17418590
[TBL] [Abstract][Full Text] [Related]
37. Generation of heavy-chain-only antibodies in mice.
Janssens R; Dekker S; Hendriks RW; Panayotou G; van Remoortere A; San JK; Grosveld F; Drabek D
Proc Natl Acad Sci U S A; 2006 Oct; 103(41):15130-5. PubMed ID: 17015837
[TBL] [Abstract][Full Text] [Related]
38. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
Presta LG
Adv Drug Deliv Rev; 2006 Aug; 58(5-6):640-56. PubMed ID: 16904789
[TBL] [Abstract][Full Text] [Related]
39. Engineered antibodies accelerating drug discovery and development.
Zhu Z
IDrugs; 2001 Dec; 4(12):1346-8. PubMed ID: 15931562
[TBL] [Abstract][Full Text] [Related]
40. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Feb; 96(2):381-91. PubMed ID: 16937408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
